首页 / 院系成果 / 成果详情页

Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial 期刊论文

编号：

388D4C147CCC69B352CF7DE7D1C6E6F8
作者：

Ding, YuMing#^[1,2,3]Zhang, QiuMei^[4];Li, RuiLi^[5];Han, ZhongXue^[1,2,3];Zhao, Qing^[6];Xu, LiDong^[7];Wang, KeYu^[7];Nan, XuePing^[1,2,3];Duan, Miao^[1,2,3];Zeng, ShuYan^[1,2,3];Kong, QingZhou(孔庆周)^[1,2,3]Wang, Hui^[1,2,3];Wu, XiaoQi^[1,2,3];Zhang, Ning^[8];Li, YanQing(李延青)^[1,2,3]Zuo, XiuLi(左秀丽)*^[1,2,3]Li, YueYue(李月月)*^[1,2,3]
语种：

英文
期刊：

HELICOBACTER ISSN：1083-4389 2024 年 29 卷 4 期 ; JUL
Associated data：

ClinicalTrials.gov/NCT05431075
收录：
关键词：

antibiotic dose Helicobacter pylori tetracycline
摘要：

Background: Current guidelines recommend bismuth-containing quadruple therapy for patients newly diagnosed with Helicobacter pylori (H. pylori) infection. We aimed to compare the efficacy and safety of tetracycline administered three times daily versus four times daily in bismuth-containing quadruple therapy for first-line treatment of H. pylori infection. Methods: This multicenter, noninferiority, randomized controlled study, conducted in China, recruited treatment-na & iuml;ve adults with H. pylori infection, randomized 1:1 into two treatment groups to receive either of the following bismuth-containing quadruple therapies: esomeprazole 20 mg twice-daily; bismuth 220 mg twice-daily; amoxicillin 1000 mg twice-daily; and tetracycline 500 mg three times daily (TET-T) versus 500 mg four times daily (TET-F). At least 6 weeks post-treatment, a C-13-urea breath test was performed to evaluate H. pylori eradication. Results: In total, 406 patients were randomly assigned to the two treatment groups. Intention-to-treat eradication rates were 91.63% (186/203; 95% confidence interval [CI] 87.82%-95.44%) versus 90.15% (183/203; 95% CI 86.05%-94.25%) (p = 0.0005) and per-protocol eradication rates were 95.34% (184/193; 95% CI 92.36%-98.31%) versus 95.72% (179/187; 95% CI 92.82%-98.62%) (p = 0.0002) for the TET-T and TET-F group, respectively. TET-T-treated patients had a lower incidence of adverse effects than TET-F-treated patients (21.61% vs. 31.63%, p = 0.024), with no significant differences in compliance to treatment between the groups. Conclusion: As a first-line therapy for H. pylori infection, the eradication rate of the TET-T therapy was noninferior to that of the TET-F therapy while significantly reducing the incidence of adverse reactions. Trial Registration: ClinicalTrials.gov identifier: NCT05431075
推荐引用方式
GB/T 7714：

Ding Yu-Ming,Zhang Qiu-Mei,Li Rui-Li, et al. Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial [J].HELICOBACTER,2024,29(4).
APA：

Ding Yu-Ming,Zhang Qiu-Mei,Li Rui-Li,Han Zhong-Xue,&Li Yue-Yue.(2024).Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial .HELICOBACTER,29(4).
MLA：

Ding Yu-Ming, et al. "Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial" .HELICOBACTER 29,4(2024).
入库时间：

9/1/2024 12:31:11 AM
更新时间：

10/20/2024 11:14:43 PM
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：8  下载次数：0

分享到：

浏览次数：8

下载次数：0

打印次数：0